Last update 01 Nov 2024

Diffuse Alopecia

Last update 01 Nov 2024

Basic Info

Synonyms

Diffuse alopecia, Diffuse alopecia (disorder), alopecia diffuse

+ [6]

Introduction-

Drugs associated with Diffuse Alopecia

Carpronium Chloride

Target-

Mechanism-

Active Org.

Nipro Pharma Corp.

Originator Org.

Nipro Pharma Corp.

Active Indication

Diffuse Alopecia

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date18 Apr 1968

Clinical Trials associated with Diffuse Alopecia

NCT05098600 / CompletedNot ApplicableIIT

The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Cross-sectional and Cohort Study

The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a dermatology clinic of a metropolitan hospital.

Start Date15 Oct 2021

Sponsor / Collaborator

University Hospital Královské Vinohrady

100 Clinical Results associated with Diffuse Alopecia

100 Translational Medicine associated with Diffuse Alopecia

0 Patents (Medical) associated with Diffuse Alopecia

426

Literatures (Medical) associated with Diffuse Alopecia

01 Sep 2024·Actas Dermo-Sifiliográficas

Actualización de la tricodinia, un reto para los dermatólogos

Article

Author: Saceda-Corralo, D ; Saceda-Corralo, D. ; Imbernon-Moya, A ; Vano-Galvan, S ; Rodriguez-Tamez, G ; Rodriguez-Tamez, G. ; Vano-Galvan, S. ; Imbernon-Moya, A.

Trichodynia is the sensation of pain in the scalp, which, in most cases, is associated with certain types of alopecia. Despite being a term coined by Rebora back in 1996 to described patients with diffuse alopecia consistent with telogen effluvium, this symptom has currently been reported in other entities. Androgenic alopecia, scarring alopecia, alopecia areata, trichotillomania, and chemotherapy-induced alopecia are common causes of trichodynia. Similarly, its association with psychiatric comorbidities, including depression, anxiety, obsessive-compulsive disorder and somatoform disorders has been reported with a higher prevalence among women. Although its pathogenesis is still to be elucidate, some factors involved are substanceP, psychiatric comorbidities and perifollicular inflammation. Clinically it exhibits pain or discomfort of the scalp, almost always in association with hair los. The sensation of pain can occur throughout the scalp or locally in some specific areas. Diagnosis is clinical and one of exclusion. Regarding treatment, there are no specific therapies for trichodynia. However, the use of botulinum toxinA, antidepressants, neuromodulators, propranolol, topical corticosteroids, oral corticosteroids and topical cannabinoids are therapeutic alternatives that should be taken into consideration. Since treatment of trichodynia is still therapeutically challenging for dermatologists more prospective studies are needed to evaluate new therapies.

01 Sep 2024·American family physician

Hair Loss: Diagnosis and Treatment.

Review

Author: Forde, Klive M ; Dakkak, MaryAnn ; Lanney, Howard

More than 80 million people in the United States are affected by hair loss, also known as alopecia. Nonscarring alopecias are categorized as diffuse, patterned, or focal. Diffuse alopecias include telogen and anagen effluvium, are usually self-limited, and depend on stopping the underlying cause (e.g., stress). Patterned hair loss, specifically androgenetic alopecia, is the most common form of alopecia; it is typically genetic, and first-line treatment is minoxidil. Oral finasteride is another treatment available for male patients. Focal hair loss includes alopecia areata, which is typically self-limited and treated with intralesional corticosteroid or oral immunosuppressant therapy; tinea capitis, which is treated with oral antifungals; and traction alopecia, which is treated by decreasing tension on the hair. Hair loss can be caused by several systemic diseases. A comprehensive history and physical examination, with targeted laboratory testing, may elucidate malnutrition, autoimmune diseases, and endocrine disease. Patients with moderate to severe hair loss are more likely to have accompanying anxiety, depression, and lower work productivity and quality-of-life scores. Educating patients about expected hair changes, treatment options, and realistic outcomes can help patients feel that they are being listened to and that their hair loss is being taken seriously.

01 Apr 2024·Skin Research and Technology

Diagnostic and grading criteria for androgenetic alopecia using dermoscopy

Article

Author: Zhu, Yueqian ; Wang, Miaomiao ; Li, Zonghui ; Wang, Yuting ; Zhou, Naihui ; Ding, Wei ; Sun, Shiquan ; Yao, Manxue ; Li, Yan ; Yang, Mengyao ; Wang, Lu

AbstractObjectivesTo establish accurate and objective dermoscopic diagnostic criteria and grading standards for males and females with androgenetic alopecia (AGA).MethodsTwenty patients each with AGA, diffuse alopecia areata, telogen effluvium, and healthy controls were enrolled in the current study. In addition, 60 patients with grades F1/V1, F2/V2, and F3/V3 AGA (20 cases each) were enrolled. The patients underwent dermoscopic examinations. The sensitivity and specificity of the diagnostic criteria were based on the 60 AGA and 60 non‐AGA. In addition, 150 patients diagnosed with AGA clinically and by dermoscopy were enrolled to calculate the accuracy of the grading criteria.ResultsThe diagnostic criteria included primary, secondary, and exclusion criteria. The grading criteria included three indices, which divided the severity of AGA into grades 1, 2, and 3. The sensitivity and specificity of the diagnostic criteria were 98.3% and 96.7% respectively. The accuracy of grade 1, 2, and 3 dermoscopic grading criteria were 96%, 92%, and 100% respectively, with a total accuracy of 96%.LimitationsTo test the diagnostic and grading criteria, more patients need to be collected.ConclusionsThe dermoscopic diagnostic and grading criteria are objective with good accuracy, which could provide a reasonable basis for the early diagnosis, grading treatment, and improved prognosis for AGA.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Diffuse Alopecia

Basic Info

Related

Analysis